Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide

NCT02638805 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

136

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: ITCA 650 Osmotic Mini Pump 20/60 mcg/day
DRUG: ITCA 650 Osmotic Mini Pump 60 mcg/day
DRUG: Metformin
DRUG: Liraglutide

Sponsor

Intarcia Therapeutics